Form 13-F position report

EDGEWISE THERAPEUTICS INC

Reported by PRICE T ROWE ASSOCIATES INC MD

EWTX CUSIP 28036F105 Manager CIK 0000080255

Reported 294,881 shares, up 265,831 (915.1%) from the prior quarter.

Reported value 736.1%; share count 915.1% vs. the prior quarter.

Added
% of reported 13F value < 0.01% This manager · Q1 2025
Shares 294,881 Quarter-end amount reported
Reported value $6,488,000 Fair value at quarter end
Consecutive quarters held 13 Through Q1 2025

Reported position value by quarter

Reported position value by quarter

Each bar is a Form 13-F quarter-end snapshot. It does not show trades made within the quarter.

Reported position value by quarter
Date Holding Value
2022-03-31 3393000
2022-06-30 2780000
2022-09-30 2522000
2022-12-31 2309000
2023-03-31 819000
2023-06-30 968000
2023-09-30 722000
2023-12-31 1380000
2024-03-31 300000
2024-06-30 416000
2024-09-30 636000
2024-12-31 776000
2025-03-31 6488000
2025-06-30 665000
2025-09-30 834000
2025-12-31 1422000
2026-03-31 2187000
2026-06-30 33177000
2026-09-30 31427000

Quarterly position history

How this manager's reported quarter-end position changed over time.

19 quarters
Quarterly reported position history for EDGEWISE THERAPEUTICS INC held by PRICE T ROWE ASSOCIATES INC MD.
Quarter Activity Shares Change % of reported 13F Reported value Filed Source filing
Q3 2026 Reduced 774,046 -42,472 (-5.2%) < 0.01% $31,427,000 2026-11-16
Q2 2026 Added 816,518 +747,091 (1076.1%) < 0.01% $33,177,000 2026-08-14
Q1 2026 Added 69,427 +12,112 (21.1%) < 0.01% $2,187,000 2026-05-15
Q4 2025 Added 57,315 +5,929 (11.5%) < 0.01% $1,422,000 2026-02-17
Q3 2025 Added 51,386 +704 (1.4%) < 0.01% $834,000 2025-11-14
Q2 2025 Reduced 50,682 -244,199 (-82.8%) < 0.01% $665,000 2025-08-14
Q1 2025 Added 294,881 +265,831 (915.1%) < 0.01% $6,488,000 2025-05-14
Q4 2024 Added 29,050 +5,242 (22.0%) < 0.01% $776,000 2025-02-14
Q3 2024 Added 23,808 +722 (3.1%) < 0.01% $636,000 2024-11-14
Q2 2024 Added 23,086 +6,662 (40.6%) < 0.01% $416,000 2024-08-14
Q1 2024 Reduced 16,424 -109,647 (-87.0%) < 0.01% $300,000 2024-05-15
Q4 2023 Added 126,071 +367 (0.3%) < 0.01% $1,380,000 2024-02-14
Q3 2023 Added 125,704 +1,024 (0.8%) < 0.01% $722,000 2023-11-14
Q2 2023 Added 124,680 +2,110 (1.7%) < 0.01% $968,000 2023-08-14
Q1 2023 Reduced 122,570 -135,756 (-52.6%) < 0.01% $819,000 2023-05-15
Q4 2022 Added 258,326 +2,088 (0.8%) < 0.01% $2,309,000 2023-02-14
Q3 2022 Reduced 256,238 -92,985 (-26.6%) < 0.01% $2,522,000 2022-11-14
Q2 2022 Reduced 349,223 -552 (-0.2%) < 0.01% $2,780,000 2022-08-15
Q1 2022 New 349,775 +349,775 (0.0%) < 0.01% $3,393,000 2022-05-16

Who else reported the position

231 managers reported EDGEWISE THERAPEUTICS INC for Q1 2025.

Managers reporting EDGEWISE THERAPEUTICS INC in Q1 2025.
Manager Activity Shares Change % of reported 13F Reported value Tenure
ORBIMED ADVISORS LLC Unchanged 15,021,721 0 7.9% $330,477,862 17 qtrs
RA CAPITAL MANAGEMENT L P Unchanged 8,909,091 0 3.27% $196,000,002 5 qtrs
PERCEPTIVE ADVISORS LLC Added 6,547,328 +3,861,791 5.09% $144,041,216 6 qtrs
BlackRock Inc Added 6,485,008 +5,993 < 0.01% $142,670,176 3 qtrs
BAKER BROS ADVISORS LP Unchanged 6,155,940 0 1.5% $135,430,680 17 qtrs
JANUS HENDERSON GROUP PLC Added 5,282,154 +298,214 0.07% $122,854,879 17 qtrs
Novo Holdings A S Added 5,350,000 +350,000 8.95% $117,700,000 17 qtrs
Paradigm Biocapital Advisors LP Reduced 4,394,556 -99,373 4.43% $96,680,232 5 qtrs
VANGUARD GROUP INC Reduced 4,294,404 -172,445 < 0.01% $94,476,888 17 qtrs
Cormorant Asset Management LP Added 4,101,992 +695,458 6.79% $90,243,824 17 qtrs
Premium adds each manager's conviction percentile across reporting peers.
Filing details and methodology As reported
Report period
March 31, 2025
Filed
May 14, 2025
Filing type
13F-HR
Position type
COMM STK

Voting authority reported

Sole
294,881
Shared
0
None
0

“None” means the manager reported no voting authority for those shares on non-routine matters. It does not disclose why and is not evidence of securities lending.

Form 13-F is a delayed quarter-end snapshot of disclosed long Section 13(f) securities. It can be filed up to 45 days after quarter end, excludes short positions and most non-U.S. securities, and does not reveal intra-quarter trading. For options, reported shares and value describe the underlying-share exposure; strike, expiry, premium, and written positions are not disclosed.